Tbio ATG10 Ubiquitin-like-conjugating enzyme ATG10

Protein Summary

Description

E2-like enzyme involved in autophagy. Acts as an E2-like enzyme that catalyzes the conjugation of ATG12 to ATG5. ATG12 conjugation to ATG5 is required for autophagy. Likely serves as an ATG5-recognition molecule. Not involved in ATG12 conjugation to ATG3 (By similarity). Plays a role in adenovirus-mediated cell lysis. Autophagy is a process for the bulk degradation of cytosolic compartments by lysosomes. ATG10 is an E2-like enzyme involved in 2 ubiquitin-like modifications essential for autophagosome formation: ATG12 (MIM 609608)-ATG5 (MIM 604261) conjugation and modification of a soluble form of MAP-LC3 (MAP1LC3A; MIM 601242), a homolog of yeast Apg8, to a membrane-bound form (Nemoto et al., 2003 [PubMed 12890687]).[supplied by OMIM, Mar 2008]

Uniprot Accession IDs

• Q9H0Y0
• B2RE09
• Q6PIX1
• Q9H842

Gene Name

• ATG10

Ensembl ID

• ENST00000282185
• ENSP00000282185
• ENSG00000152348
• ENST00000355178
• ENSP00000347309
• ENST00000458350
• ENSP00000404938
• ENST00000513443
• ENSP00000425182

Symbol

• APG10L
• APG10
• APG10L
• pp12616

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
histone modification site profile	0.92
virus perturbation	0.76
small molecule perturbation	0.7
transcription factor binding site profile	0.7
transcription factor perturbation	0.68

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 59.86   (req: < 5)

Gene RIFs: 15   (req: <= 3)

Antibodies: 334   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 59.86   (req: >= 5)

Gene RIFs: 15   (req: > 3)

Antibodies: 334   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 8

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0